Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2.
Malic enzyme 2 (ME2) is a mitochondrial enzyme that catalyzes the conversion of malate to pyruvate and CO2 and uses NAD as a cofactor. Higher expression of this enzyme correlates with the degree of cell de-differentiation. We found that ME2 is expressed in K562 erythroleukemia cells, in which a number of agents have been found to induce differentiation either along the erythroid or the myeloid lineage. We found that knockdown of ME2 led to diminished proliferation of tumor cells and increased apoptosis in vitro. These findings were accompanied by differentiation of K562 cells along the erythroid lineage, as confirmed by staining for glycophorin A and hemoglobin production. ME2 knockdown also totally abolished growth of K562 cells in nude mice. Increased ROS levels, likely reflecting increased mitochondrial production, and a decreased NADPH/NADP+ ratio were noted but use of a free radical scavenger to decrease inhibition of ROS levels did not reverse the differentiation or apoptotic phenotype, suggesting that ROS production is not causally involved in the resultant phenotype. As might be expected, depletion of ME2 induced an increase in the NAD+/NADH ratio and ATP levels fell significantly. Inhibition of the malate-aspartate shuttle was insufficient to induce K562 differentiation. We also examined several intracellular signaling pathways and expression of transcription factors and intermediate filament proteins whose expression is known to be modulated during erythroid differentiation in K562 cells. We found that silencing of ME2 leads to phospho-ERK1/2 inhibition, phospho-AKT activation, increased GATA-1 expression and diminished vimentin expression. Metabolomic analysis, conducted to gain insight into intermediary metabolic pathways that ME2 knockdown might affect, showed that ME2 depletion resulted in high orotate levels, suggesting potential impairment of pyrimidine metabolism. Collectively our data point to ME2 as a potentially novel metabolic target for leukemia therapy.
Ren
Jian-Guo
JG
Divisions of Interdisciplinary Medicine and Biotechnology, Hematology-Oncology and Nephrology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts, United States of America.
Seth
Pankaj
P
Everett
Peter
P
Clish
Clary B
CB
Sukhatme
Vikas P
VP
D000818:Animals; D017209:Apoptosis; D002454:Cell Differentiation; D049109:Cell Proliferation; D041905:Erythroid Cells / Q000166:cytology* / Q000201:enzymology*; D055786:Gene Knockout Techniques; D006801:Humans; D020014:K562 Cells; D004915:Leukemia, Erythroblastic, Acute / Q000201:enzymology* / Q000235:genetics / Q000503:physiopathology*; D008291:Malate Dehydrogenase / Q000172:deficiency* / Q000235:genetics; D051379:Mice
D008291:Malate Dehydrogenase; C495394:malic enzyme 2; human
Blood. 2000 Apr 1;95(7):2391-6
10733512
Science. 1997 Mar 14;275(5306):1649-52
9054359
J Biol Chem. 2007 Dec 7;282(49):35657-65
17928289
Nat Methods. 2006 Sep;3(9):715-9
16929317
Int J Biochem Cell Biol. 2009 Mar;41(3):570-7
18694847
Nat Med. 1996 May;2(5):561-6
8616716
Blood. 2009 May 7;113(19):4512-20
19066393
J Biol Chem. 2007 Jan 5;282(1):200-7
17102138
Blood. 2000 Sep 15;96(6):2284-91
10979978
Cancer Lett. 1985 Aug;28(1):35-42
4027954
Leuk Res. 2004 Jun;28(6):623-9
15120940
Cancer Cell. 2005 Oct;8(4):311-21
16226706
Biochem Biophys Res Commun. 1973 Jan 23;50(2):524-31
4144006
Nature. 2006 May 25;441(7092):451-6
16724057
Toxicol In Vitro. 2008 Sep;22(6):1503-10
18586450
Mol Pharmacol. 2002 Sep;62(3):463-72
12181422
J Biol Chem. 1979 Apr 25;254(8):2669-76
429309
Cancer Res. 1969 Jun;29(6):1195-9
4307782
Biochem Biophys Res Commun. 1999 Oct 5;263(3):790-6
10512759
J Biol Chem. 1980 May 10;255(9):3844-8
7372652
Am J Hum Genet. 2005 Jan;76(1):139-46
15532013
Am J Pathol. 2009 Mar;174(3):1017-26
19179610
J Biol Chem. 2006 Oct 13;281(41):30593-602
16912049
Leuk Res. 1995 Apr;19(4):263-73
7538618
Mol Cell. 2002 May;9(5):1031-44
12049739
FASEB J. 2003 Nov;17(14):2160-2
14597677
Cancer Res. 1988 Feb 1;48(3):602-8
3335023
Biochimie. 1992 Nov;74(11):959-74
1477140
Biochem Pharmacol. 1990 Feb 1;39(3):455-62
1968339
Free Radic Biol Med. 2008 Apr 15;44(8):1529-35
18275858
Oncogene. 2006 Feb 2;25(5):781-94
16186797
J Chromatogr A. 2007 Apr 20;1147(2):153-64
17376459
Biochem J. 1990 Jan 15;265(2):503-9
2302181
Annu Rev Biochem. 1979;48:871-922
38739
J Cell Physiol. 1990 May;143(2):310-20
1692028
Mol Cell Biochem. 2004 Mar;258(1-2):25-33
15030167
J Biol Chem. 2008 Nov 7;283(45):30461-70
18687678
Blood. 2000 Oct 1;96(7):2440-50
11001896
J Biol Chem. 1984 May 25;259(10):6215-21
6144677
Nat Rev Cancer. 2007 Oct;7(10):763-77
17882277
Biochem Pharmacol. 2006 Sep 14;72(6):671-80
16828058
J Cell Physiol. 2004 Mar;198(3):370-6
14755542
Cancer Res. 1986 Nov;46(11):5589-91
3756905
Tissue Cell. 2002 Feb;34(1):33-8
11989968
Biol Reprod. 2009 Feb;80(2):295-301
18971426
Mol Cell Biol. 2009 Mar;29(5):1163-75
19103751
Cell Biol Int. 1998;22(1):41-9
9828081
J Biol Chem. 2000 Aug 11;275(32):24273-8
10833515
CRC Crit Rev Biochem. 1981;11(4):341-93
6118236
Physiol Genomics. 2004 Apr 13;17(2):140-9
14747661
Psychiatry Res. 2007 Feb 28;150(1):1-11
17258816
Cancer Cell. 2006 Sep;10(3):241-52
16959615
J Cell Physiol. 1989 May;139(2):370-6
2715192
J Biol Chem. 2001 Jan 5;276(1):522-8
11016926
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10465-9
17563371
J Biol Chem. 2001 Apr 20;276(16):13186-91
11278385
Cell Biol Int. 2004;28(5):403-10
15193284
J Biol Chem. 1991 Feb 15;266(5):3016-21
1993674
Cell Growth Differ. 2001 Sep;12(9):481-6
11571231
Leuk Res. 1995 Mar;19(3):203-12
7700081
Biochemistry. 2005 Sep 27;44(38):12737-45
16171388
J Biol Chem. 2001 Oct 12;276(41):37747-53
11489902
FEBS Lett. 2004 Nov 19;577(3):361-6
15556610
J Biol Chem. 1980 May 10;255(9):3849-54
7372653
Eur J Cancer. 1976 Apr;12(4):299-303
60240